LLY
Eli Lilly and Company · Healthcare · Drug Manufacturers - General
Momentum-Eingaben (vergleichbare Manager): Halterbreite 0.0% · Aktienfluss -3.2% · neue Nettopositionen 0.0% — Formel
Alle Eigentumszahlen: nur beobachtete 13F-Manager, Stammaktienpositionen, Berichtszeitraum Q1 2025
| Quartal | Inhaber | Δ | Aktien | Gemeldeter Wert | Neu | Ausstiege |
|---|---|---|---|---|---|---|
| Q2 2026 | 193 | +4 | 671.92M | $804.91B | +6 | −1 |
| Q1 2026 | 191 | -3 | 666.59M | $613.20B | +1 | −5 |
| Q4 2025 | 193 | +2 | 707.04M | $758.81B | +3 | — |
| Q3 2025 | 27 | -3 | 329.88M | $251.63B | +2 | −6 |
| Q2 2025 | 28 | -1 | 307.45M | $239.60B | +2 | −3 |
| Q1 2025 | 26 | 0 | 140.32M | $115.83B | +1 | −1 |
| Q4 2024 | 26 | +1 | 145.00M | $111.91B | +3 | −2 |
| Q3 2024 | 24 | +2 | 109.89M | $97.29B | +2 | — |
| Q2 2024 | 22 | — | 112.43M | $101.75B | — | — |
| # | Manager | Aktien | Δ Anteile | Wert | Deren Gewichtung | Gehalten | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passiv) | 34.44M | +0.4% | $28.44B | 1.2% | ▲ Add | 2 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 19.13M | -8.3% | $15.80B | 2.0% | ▼ Trim | 4 | SEC ↗ |
| 3 | T. Rowe Price ✦ | 19.13M | -8.3% | $15.80B | 2.0% | ▼ Trim | 4 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passiv) | 18.53M | +6.6% | $15.25B | 1.2% | ▲ Add | 4 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passiv) | 18.53M | +6.6% | $15.25B | 1.2% | ▲ Add | 4 | SEC ↗ |
| 6 | Capital World Investors ✦ | 18.38M | -6.0% | $15.18B | 2.5% | ▼ Trim | 4 | SEC ↗ |
| 7 | PRIMECAP Management ✦ | 14.78M | -11.8% | $12.21B | 10.1% | ▼ Trim | 4 | SEC ↗ |
| 8 | Wellington Management ✦ | 12.71M | +0.7% | $10.50B | 2.0% | ▲ Add | 4 | SEC ↗ |
| 9 | Wellington Management ✦ | 12.71M | +0.7% | $10.50B | 2.0% | ▲ Add | 4 | SEC ↗ |
| 10 | Wellington Management ✦ | 12.71M | +0.7% | $10.50B | 2.0% | ▲ Add | 4 | SEC ↗ |
| 11 | Wellington Management ✦ | 12.71M | +0.7% | $10.50B | 2.0% | ▲ Add | 4 | SEC ↗ |
| 12 | Wellington Management ✦ | 12.71M | +0.7% | $10.50B | 2.0% | ▲ Add | 4 | SEC ↗ |
| 13 | Wellington Management ✦ | 12.71M | +0.7% | $10.50B | 2.0% | ▲ Add | 4 | SEC ↗ |
| 14 | Wellington Management ✦ | 12.71M | +0.7% | $10.50B | 2.0% | ▲ Add | 4 | SEC ↗ |
| 15 | Wellington Management ✦ | 12.71M | +0.7% | $10.50B | 2.0% | ▲ Add | 4 | SEC ↗ |
| 16 | Wellington Management ✦ | 12.71M | +0.7% | $10.50B | 2.0% | ▲ Add | 4 | SEC ↗ |
| 17 | Norges Bank ✦ (passiv) | 11.00M | +1.0% | $9.08B | 1.3% | ▲ Add | 4 | SEC ↗ |
| 18 | Fisher Asset Management ✦ | 5.44M | +3.9% | $4.49B | 1.9% | ▲ Add | 4 | SEC ↗ |
| 19 | Tiger Global Management ✦ | 1.33M | +1.9% | $1.10B | 4.1% | ▲ Add | 4 | SEC ↗ |
| 20 | Adage Capital Partners ✦ | 741.72K | +1.2% | $612.60M | 1.1% | ▲ Add | 4 | SEC ↗ |
| 21 | Millennium Management ✦ | 681.01K | -15.0% | $562.46M | 0.6% | ▼ Trim | 4 | SEC ↗ |
| 22 | D. E. Shaw & Co. ✦ | 573.33K | -53.8% | $473.52M | 0.6% | ▼ Trim | 4 | SEC ↗ |
| 23 | D. E. Shaw & Co. ✦ | 573.33K | -53.8% | $473.52M | 0.6% | ▼ Trim | 4 | SEC ↗ |
| 24 | AQR Capital Management ✦ | 567.50K | -11.9% | $456.15M | 0.5% | ▼ Trim | 4 | SEC ↗ |
| 25 | AQR Capital Management ✦ | 567.50K | -11.9% | $456.15M | 0.5% | ▼ Trim | 4 | SEC ↗ |
| 26 | AQR Capital Management ✦ | 567.50K | -11.9% | $456.15M | 0.5% | ▼ Trim | 4 | SEC ↗ |
| 27 | AQR Capital Management ✦ | 567.50K | -11.9% | $456.15M | 0.5% | ▼ Trim | 4 | SEC ↗ |
| 28 | AQR Capital Management ✦ | 567.50K | -11.9% | $456.15M | 0.5% | ▼ Trim | 4 | SEC ↗ |
| 29 | AQR Capital Management ✦ | 567.50K | -11.9% | $456.15M | 0.5% | ▼ Trim | 4 | SEC ↗ |
| 30 | AQR Capital Management ✦ | 567.50K | -11.9% | $456.15M | 0.5% | ▼ Trim | 4 | SEC ↗ |
| 31 | Lone Pine Capital ✦ | 551.83K | -29.5% | $455.76M | 4.0% | ▼ Trim | 2 | SEC ↗ |
| 32 | Citadel Advisors ✦ | 477.78K | -21.8% | $394.60M | 0.4% | ▼ Trim | 4 | SEC ↗ |
| 33 | Citadel Advisors ✦ | 477.78K | -21.8% | $394.60M | 0.4% | ▼ Trim | 4 | SEC ↗ |
| 34 | Marshall Wace ✦ | 419.50K | +7.9% | $346.47M | 0.5% | ▲ Add | 4 | SEC ↗ |
| 35 | Marshall Wace ✦ | 419.50K | +7.9% | $346.47M | 0.5% | ▲ Add | 4 | SEC ↗ |
| 36 | Marshall Wace ✦ | 419.50K | +7.9% | $346.47M | 0.5% | ▲ Add | 4 | SEC ↗ |
| 37 | Marshall Wace ✦ | 419.50K | +7.9% | $346.47M | 0.5% | ▲ Add | 4 | SEC ↗ |
| 38 | Coatue Management ✦ | 183.72K | -14.1% | $151.74M | 0.7% | ▼ Trim | 4 | SEC ↗ |
| 39 | Coatue Management ✦ | 183.72K | -14.1% | $151.74M | 0.7% | ▼ Trim | 4 | SEC ↗ |
| 40 | Coatue Management ✦ | 183.72K | -14.1% | $151.74M | 0.7% | ▼ Trim | 4 | SEC ↗ |
| 41 | Coatue Management ✦ | 183.72K | -14.1% | $151.74M | 0.7% | ▼ Trim | 4 | SEC ↗ |
| 42 | Coatue Management ✦ | 183.72K | -14.1% | $151.74M | 0.7% | ▼ Trim | 4 | SEC ↗ |
| 43 | Renaissance Technologies ✦ | 96.31K | +78.0% | $79.55M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 44 | Duquesne Family Office ✦ | 94.83K | +52.5% | $78.32M | 2.6% | ▲ Add | 2 | SEC ↗ |
| 45 | Point72 Asset Management ✦ | 54.77K | Neu | $45.24M | 0.1% | New | 1 | SEC ↗ |
| 46 | Dodge & Cox ✦ | 45.09K | +0.7% | $37.24M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 47 | Arrowstreet Capital ✦ | 41.41K | +178.9% | $34.20M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 48 | GAMCO Investors ✦ | 30.07K | -10.3% | $24.84M | 0.3% | ▼ Trim | 4 | SEC ↗ |
| 49 | Two Sigma Investments ✦ | 15.73K | -95.1% | $12.99M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 50 | Gotham Asset Management ✦ | 7.55K | +30.6% | $6.23M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 51 | Bridgewater Associates ✦ | 2.75K | -96.7% | $2.27M | 0.0% | ▼ Trim | 4 | SEC ↗ |
„Ihre Gewichtung" = Anteil der Position am gemeldeten 13F-Eigenkapitalwert des jeweiligen Managers — das Conviction-Maß. ✦ = kuratorisch ausgewählter Manager.
Neue Käufer
| Point72 Asset Management | $45.24M | 0.1% |
Ausgestiegen
| Soros Fund Management | $25.97M | war 0.7% |
Marktweiter Kontext: über ALLE 13F-Melder (strukturierte SEC-Daten, Q1 2026): 4,323 Inhaber, 762.84M Anteile, $674.93B gemeldet. Dies ist ein anderer, älterer Zeitraum als die oben genannten Zahlen des erfassten Universums; beide werden niemals vermischt.
Was die erfassten Halter dieses Wertpapiers am häufigsten sonst noch halten — Zählungen gemeinsamer Eigentümerschaft, keine fundamentalen Zusammenhänge.
Käufe auf dem offenen Markt (P)
Keine Insider-Käufe auf dem offenen Markt in unserem Erfassungszeitraum.
Verkäufe auf dem offenen Markt (S)
Officer · 6.50K Ant. · $7.64M
Officer · 2.00K Ant. · $2.37M
Officer · 5.00K Ant. · $5.95M
Zuteilungen, Ausübungen und Steuereinbehalte werden hier nie als Käufe oder Verkäufe gezählt. Methodik
The Food and Drug Administration has cleared a new blood test from Roche and Eli Lilly designed to help identify…
ForbesThe Food and Drug Administration cleared a blood test for identifying Alzheimer's disease symptoms, which was developed…
WSJThe U.S. Food and Drug Administration has cleared Roche and partner Eli Lilly's blood test to help identify signs of…
ReutersThe once-daily pill was approved for patients with a body mass index of at least 30, or between 27 and 30 in the event…
WSJEli Lilly said on Monday it has launched its oral pill, Foundayo, in the UK for weight management and type 2…
Reuters